Multimodal therapy, specifically neoadjuvant chemotherapy, was associated with increased survival in patients with diffuse type gastric and gastroesophageal junction carcinoma, including signet ring cell carcinoma. All-cause mortality within 90 days postoperatively was lower after neoadjuvant chemotherapy compared to primary surgery. Additionally, mortality remained lower in the neoadjuvant chemotherapy group even after 90 days post-surgery. These findings suggest the potential benefit of neoadjuvant chemotherapy in improving outcomes for patients with these types of cancers.
Journal Article by Gertsen EC, van der Veen A (…) Ruurda JP et 9 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.